Meeder Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Meeder Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-179	Closed	-$5K	–	1088
2021 Q3	$5K	Buy	179 +3	+2%	+$96	﹤0.01%	1906
2021 Q2	$7K	Hold	176	–	–	﹤0.01%	1811
2021 Q1	$9K	Buy	+176	New	+$9.7K	﹤0.01%	1620
2020 Q4	–	Sell	-3	Closed	–	–	1836
2020 Q3	$0	Hold	3	–	–	﹤0.01%	2144
2020 Q2	$0	Sell	3 -51	-94%	-$3.52K	﹤0.01%	2004
2020 Q1	$3K	Buy	54 +36	+200%	+$2.4K	﹤0.01%	1921
2019 Q4	$1K	Buy	+18	New	+$1.27K	﹤0.01%	2104
2019 Q1	–	Sell	-6	Closed	-$1K	–	1683
2018 Q4	$1K	Buy	+6	New	+$1.31K	﹤0.01%	1614
2018 Q3	–	Sell	-1	Closed	-$240	–	1516
2018 Q2	$240	Buy	+1	New	+$437	﹤0.01%	1538
2018 Q1	–	Sell	-23	Closed	-$9K	–	1543
2017 Q4	$9K	Buy	23 +19	+475%	+$7.86K	﹤0.01%	1140
2017 Q3	$2K	Buy	+4	New	+$1.07K	﹤0.01%	1435

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's ABEO Position: Q4 2021 in Review

Meeder Asset Management sold out of Abeona Therapeutics (ABEO) in Q4 2021, closing a stake of 179 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in ABEO in Q3 2017 and held it in 11 quarters. The position peaked at $9K in Q1 2021. 52 funds tracked by Wall St. Rank hold ABEO as of Q4 2021.

Meeder Asset Management reported no remaining Abeona Therapeutics position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 179 Abeona Therapeutics shares in Q4 2021, an estimated $5K.
Meeder Asset Management first reported a position in Abeona Therapeutics in Q3 2017 and held it in 11 quarters.
Meeder Asset Management's Abeona Therapeutics position peaked at $9K in Q1 2021.
52 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.